Navigation Links
Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer

CAMBRIDGE, Mass., July 24, 2014 /PRNewswire/ -- Blueprint Medicines (Blueprint), a leader in discovering highly selective kinase inhibitors for genomically defined cancer patients, today announced the appointment of Jeffrey Albers as chief executive officer (CEO). Mr. Albers joins Blueprint from Algeta ASA, where he served on the executive management team as U.S. president prior to the acquisition by Bayer. Mr. Albers succeeds Alexis Borisy, co-founder and interim CEO of Blueprint and Partner at Third Rock Ventures, who will remain an active member of the Board of Directors.

"Jeff's demonstrated excellence in commercial preparation and execution, business development and team building will be invaluable as we continue to grow Blueprint and advance our pipeline of highly selective kinase drugs into clinical development and ultimately the market," said Daniel Lynch, executive chairman of Blueprint. "While we look ahead to the Company's next phase, the Blueprint Board would like to thank Alexis for his many contributions to Blueprint's successes."

Mr. Albers brings more than 20 years of experience as a life sciences executive with a track record of leading fully integrated organizations, successfully launching products and achieving aggressive revenue targets. At Algeta, Mr. Albers oversaw the commercial and business functions during a period of exponential growth in staff and revenue. Before Algeta, Mr. Albers spent seven years at Genzyme, where he served most recently as vice president of the U.S. hematology & oncology business unit. Mr. Albers holds a Masters of Business Administration and a Juris Doctor from Georgetown University. 

"Leading and growing the talented Blueprint team as we take two potential breakthrough product candidates into clinical trials while continuing to build a strong, sustainable pipeline is extremely exciting," said Mr. Albers. "I look forward to lending my experience from oncology and rare genetic diseases to accelerate Blueprint's progress toward discovering, developing and commercializing transformative medicines for genomically defined patients in need."

About Blueprint Medicines
Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer patients. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel small molecule library of kinase inhibitors, enabling Blueprint to rapidly develop potent, highly selective compounds against clear genomic driver targets. Founded in 2011, Blueprint is privately held and initially backed by Third Rock Ventures and Fidelity BioSciences. For more information, please visit

Investor Relations:
Beth DelGiacco
Stern Investor Relations, Inc.
212 362 1200

Media Relations:
David Polk
Chandler Chicco Companies
310 309 1029

Photo -

SOURCE Blueprint Medicines
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Worlds Only USDA Certified Organic and FDA Registered Homeopathic Medicines Guaranteed to Work
2. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
3. Warning: Not All Cold Sore Medicines Are Created Equal
4. Kick Off Summer Vacation With Five Simple Tips to Safely Store Medicines While Traveling
5. Global pharmaceutical industry calls for broad-based cooperation to fight online sales of counterfeit medicines around the world
6. Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines
7. New Research Reveals Extent of Poor-Quality Antimalarial Medicines in South American Countries
8. Watson Applauds GPhA Study Demonstrating $1 Trillion in Prescription Drug Savings from Generic Medicines
9. Sigma-taus Antimalarial Awarded "Project of the Year" 2011 by Medicines for Malaria Venture
10. National Community Pharmacists Association and Purdue Pharma Urge Americans to Safeguard Rx Medicines This Holiday Season
11. PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:11/26/2015)... UTRECHT, the Netherlands , November 26, 2015 /PRNewswire/ ...   A new combination approach blends immunotherapy ... --> A new combination approach blends immunotherapy with ... A new combination approach blends immunotherapy with ... the Netherlands has found that immunotherapy ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Care Market by Type (Dressings, Therapy Devices, Active Wound ... Out-Patient Facility), and Geography - Global Forecast to 2020" ... --> --> The purpose of this ... of the global advanced wound care market. It involves ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced ... User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics ... software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in ... for mental health and wellness consultation, has collaborated with a leading web-based marketplace ... knowledge gap experienced by parents and bring advice from parenting experts within their ...
(Date:11/27/2015)... ... , ... Dr. Thomas Dunlap and Dr. Patrick Coleman , ... Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted ... similar ways and require time-critical intervention to avoid large area heart damage and progressive ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... Representative. As a franchise owner, Somu now offers travelers, value and care based ... packages, private cruise sales, as well as, cabin upgrades and special amenities such ...
Breaking Medicine News(10 mins):